Pleasanton, Calif.-based 10x Genomics Inc. entered a definitive agreement to acquire Boston-based Readcoor Inc., developer of foundational in situ technologies, for cash and stock consideration of $350 million. The announcement follows 10x Genomics’ acquisition of Stockholm-based Cartana AB, developers of in situ RNA analysis technology, in late August. In situ approaches will give scientists the ability to measure large numbers of molecules directly in tissue by capturing the precise location of those molecules at sub-cellular resolution. These approaches are complementary to the company’s existing Chromium Single Cell and Visium Spatial platforms, it said. 10x will fund both transactions with a combination of cash from its balance sheet as well as stock. The company expects the Readcoor acquisition to be completed later this month subject to Readcoor shareholder approval and customary closing conditions. Goldman Sachs & Co. LLC is acting as financial advisor to Readcoor. The Cartana acquisition has been fully completed.
San Francisco-based 1Health.io, a company that provides precision testing as a service, says more than 100 new partners have signed on to deploy COVID-19 saliva-based testing across the U.S. Partners will use the company’s centralized data and logistics platform.
Carlsbad, Calif.-based Biologica Technologies Inc. reported the introduction and initial usage of their growth factor enriched cellular bone matrix (CBM), Osseogen. Osseogen CBM contains all three elements needed for bone regeneration; osteoconductivity, osteoinductivity and osteogenicity and is supplied via an open-bore syringe for easy dispensing.
New York-based Clear, the secure identity company, and Seacacus, N.J.-based Quest Diagnostics Inc. reported a new collaboration that aims to foster safer public environments and help reduce public health risk. This collaboration brings together Clear’s Health Pass technology with Quest's advanced COVID-19 testing capabilities. Health Pass is a new mobile app product by Clear which securely connects a person's verified identity to multiple layers of COVID-19 related insights to reduce public health risk. Health Pass connects mobile identity verification technology with real-time health surveys, data from temperature checks, and now, verified Quest Diagnostics COVID-19 test results.
New York-based Diagnostic Robotics and the joint Brown University-Lifespan Center for Digital Health in Providence, R.I., reported a new collaboration to accelerate the use of artificial intelligence and machine learning for the delivery of health care. Together, Diagnostic Robotics and Brown University will continue to enhance the health system's ability to transform managed care, improve patient outcomes, and reduce the costs of care. The collaboration will focus on overcoming some of the most challenging pain points along the care continuum, including predicting avoidable events and ensuring access to the most appropriate level of care for an individual's unique needs.
Cleveland-based Emanate Wireless has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $255,000 to conduct research and development work on a new health care IoT solution: Utilization, Condition, and Location System (UCLS). UCLS uses smart tags with sensors and machine learning algorithms to track the utilization, condition and location of medical equipment within a health care facility. The NSF funding will support pilot trials with three major hospital groups.
Louvain-la-Neuve, Belgium-based Ion Beam Applications SA, a provider of electron beam and X-ray solutions for industrial irradiation, signed a contract with Shin-Ho Instruments Co. Ltd., a subsidiary of Chc Healthcare Group in Taiwan, for an end-to-end solution based on a Rhodotron TT300 Duo. The contract is worth about €9 million (US$10.57 million) and will provide the Taiwanese market with a electron beam and X-ray solution which can be used for various industrial applications, such as the sterilization of disposable medical devices.
Imbio, a Minneapolis-based provider of artificial intelligence (AI) solutions for medical imaging analysis, has partnered with South San Francisco-based Genentech Inc., a member of the Roche Group, to develop quantitative imaging diagnostics for lung diseases. The multiyear agreement leverages Imbio's technical, regulatory and commercial expertise to build and deploy medical imaging AI technology for use in research, clinical trials and clinical practice.
Atlanta-based Medshape Inc. said that the U.S. Centers for Medicare & Medicaid Services (CMS) has issued a new ICD-10-PCS code for a sustained compression internal fixation device in both lower and upper extremity joint fusion procedures. The ICD-10 code went into effect Oct. 1.
Medtronic plc, of Dublin, reported that the first patient was implanted in its ELITE study of the Interstim Micro system that is assessing a rechargeable sacral neurostimulation (SNS) system to include all SNS indications for symptoms of overactive bladder, including urinary urge incontinence and urinary frequency, as well as nonobstructive urinary retention and fecal incontinence.
Latham, N.Y.-based Mesuron Inc. said rapid heart function analysis by the Avalon-H90 device may help identify myocarditis in post-COVID-19 patients. Avalon-H90 is a fully developed prototype that is ready to be reproduced as a product. The company is looking for partnerships to conduct a medical trial for detecting myocardial abnormalities in acute chest pain patients. The trial has been arranged with the Mayo Clinic.
Neupath Health Inc., of Mississauga, Ontario, reported an initiative to expand its digital health capabilities. Toronto-based Pivot Design Group will work with Neupath, its physicians, health care providers and patients to translate research and insights into proprietary digital health solutions designed to provide chronic pain patients with multi-modal care and the tools needed to live a complete and fulfilled life.
Opum US Inc., of La Jolla, Calif., has partnered with Tampa, Fla.-based Iprocedures, a provider of perioperative digital solutions, to advance remote management for patients pre and post orthopedic surgery.
Golden, Colo.-based Pharmajet said that its Stratis needle-free injection system will be used to deliver a vaccine against SARS-CoV-2 in a clinical trial in Australia. The DNA-based vaccine Covigen was developed by French-Thai pharmaceutical company Bionet and Melbourne-based biotech Technovalia.
Pq Bypass, of Milpitas, Calif., reported the enrollment of the final subject in the company’s DETOUR2 clinical trial. DETOUR2 is a prospective, multicenter, trial evaluating the Detour system for percutaneous femoral-popliteal bypass in patients with extremely long, complex lesions in the superficial femoral artery.
Qiagen, of Hilden, Germany, reported plans to launch an approach to viral RNA epidemiology that it said will simplify and accelerate PCR analysis and remove key testing bottlenecks for SARS-CoV-2 and other RNA viruses.
Billerica, Mass.-based Quanterix Corp. entered a nonexclusive royalty-bearing license agreement that grants Abbott Park, Ill.-based Abbott Laboratories access to Quanterix’s portfolio of bead-based technology patents for use in in vitro diagnostic applications. Under the terms of the agreement, Quanterix will receive an initial license fee, milestone fees subject to the achievement by Abbott of future development, regulatory, and launch milestones and royalties on the sale of licensed products.
Sanara Medtech Inc., a Fort Worth, Texas-based provider of wound and skin care products, said it has closed on an exclusive affiliation with Mgroup Integrated Physician Services P.A. Pursuant to this arrangement, Sanara, through its subsidiary United Wound and Skin Solutions LLC (UWSS), has agreed to provide certain management services to Mgroup. In exchange, Mgroup has agreed to provide certain in-person and telehealth related clinical services to UWSS. Mgroup's founder and CEO, Chris Morrison, will join UWSS and lead its telehealth efforts as president of telehealth services.
Tyber Medical LLC, of Bethlehem, Pa., reported the launch of a clinical study focusing on its titanium-integrated interbody fusion devices for use in the cervical and lumbar spine. The study aims to provide surgeons in the U.S. and Europe with data that supports the safety and effectiveness of these devices when used for spinal indications including degenerative disc disease, stenosis, fractural repair and other degenerative and trauma-related conditions.
Irving, Texas-based Vizient Inc. released three new evidence-based reports providing a comprehensive overview and guidance to hospitals on the appropriate implementation of emerging technologies for helping to care for COVID-19 patients. The topics covered in the reports are devices to assist ventilator weaning, extracorporeal blood filtration devices, and at-home remote monitoring. The company has published the reports on its website.
Xtant Medical Holdings Inc., a Belgrade, Mont.-based provider of surgical solutions for the treatment of spinal disorders, said it received notification from the NYSE American LLC that the company has regained compliance with all of the continued listing standards.